Med Business World

Your source for healthcare business

chronic inflammatory disease

Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Sanofi Healthcare India Pvt. Ltd. has announced a milestone in dermatological treatment with the approval of Dupixent® (dupilumab), a novel biologic medicine for adults with moderate-to-severe atopic dermatitis. Unlike traditional treatments that broadly suppress the immune system, Dupixent® specifically targets…